Working through a co-ordinated plan with:
Appointment of Chief Commercialisation Officer (appointed 10/6)
Release of Janssen Study (16/7)
Abcam manufacture agreement (today) - anticipating demand
Conferences July - November 21 - increasing awareness
I have always been of the view that Janssen will drive demand, the company will be looking to increase market share (worldwide). US approvals pending and submissions supported by Janssen.
Hopefully we start to see PromarkerD income either through commercialisation deals, tests or both in the Q3 report.
Ann: Proteomics engages Abcam to manufacture PromarkerD reagents, page-5
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
36.5¢ |
Change
-0.025(6.41%) |
Mkt cap ! $59.74M | |||
| Open | High | Low | Value | Volume |
| 38.0¢ | 38.0¢ | 36.0¢ | $70.59K | 189.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 8100 | 36.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 38.0¢ | 13645 | 1 |
View Market Depth
| Last trade - 15.59pm 29/07/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |